Arcus Biosciences (RCUS) Gains from Sales and Divestitures (2016 - 2022)

Arcus Biosciences' Gains from Sales and Divestitures history runs 7 years deep, the most recent figure standing at $500000.0 for Q4 2022.

• In Q4 2022, Gains from Sales and Divestitures rose 30.83% year-over-year to $500000.0; the TTM figure through Dec 2022 stood at $500000.0 (up 30.83% YoY), while the FY2022 annual figure was $500000.0, up 30.83% from the prior year.
• Gains from Sales and Divestitures was $500000.0 for Q4 2022 at Arcus Biosciences, up from $382183.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $500000.0 in Q4 2022 to a low of $6250.0 in Q4 2020.
• Historically, Gains from Sales and Divestitures has averaged $255225.0 across 5 years, with a median of $372774.0 in 2019.
• The sharpest annual moves came in 2020 and 2021: Gains from Sales and Divestitures sank 98.32% in 2020, then soared 6014.93% in 2021.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $14918.0 in 2018, then surged by 2398.82% to $372774.0 in 2019, then tumbled by 98.32% to $6250.0 in 2020, then jumped by 6014.93% to $382183.0 in 2021, then soared by 30.83% to $500000.0 in 2022.
• The last three Gains from Sales and Divestitures figures came in at $500000.0 (Q4 2022), $382183.0 (Q4 2021), and $6250.0 (Q4 2020), per Business Quant data.